Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Allotment

 This is in continuation to our letter dated February 26, 2019 intimating that the Board of Directors had in its meeting held on that day, approved issuance of listed/unlisted, secured/unsecured redeemable Non-Convertible Debentures, on private placement basis upto Rs.864 Crore in one or more series/tranches. We would now like to inform you that the Executive Committee of the Board of Directors of the Company had, in its meeting held on April 08, 2019, approved the allotment of 74,300 unrated, unlisted, redeemable, non-convertible debentures (NCDs), having the face value of Rs.1,00,000/- (Rupees One Lakh Only) each, aggregating to Rs.743 Crore under Series 1A, Series 1B and Series 2 NCDs. The details of the said allotment are mentioned in Annexure-A. This is for your kind information and record please.
08-04-2019
Bigul

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Allotment

 In continuation to our earlier comm dated 26.02.19 and pursuant to the approval of shareholders on 25.03.19, we would like to inform you that the Executive Committee of the Board of Directors of the Company today has issued and allotted 71,11,111 convertible warrants at a price of Rs.180/- each on a preferential basis to Investors, entitling them to subscribe to an equivalent number of equity shares of face value of Re.1/- each at a premium of Rs.179/- per share as per the provisions of Chapter V of ICDR Regulations. The warrant holders shall be entitled to exercise the warrants to subscribe to equity shares of the Company in compliance with the ICDR Regulations and the agreement between the Company and the Investors. The Company has received the upfront payment of Rs.32,00,00,000/- which is equivalent to the 25% of total consideration as per terms of preferential issue. Since the Company has allotted warrants, there is no change in the paid up eq. share capital of the Company.
08-04-2019
Bigul

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to Reg. 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that: a. Mr. Nithin Krishna Kaimal has been appointed as an Additional Director of the Company (in the capacity of Non-Executive Director) with effect from April 08, 2019. b. Mr. Bhupinder Singh has been appointed as an Additional Director of the Company (in the capacity of Non-Executive Independent Director) with effect from April 08, 2019. Furthermore, Mr. Bhupinder Singh has been appointed for a period of 5 (five) years commencing from April 08, 2019, subject to the approval of shareholders of the Company. Mr. Nithin Krishna Kaimal and Mr. Bhupinder Singh are not related to any Director of the Company. You are requested to take the above information on record.
08-04-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Rajesh Jain & Others
08-04-2019
Bigul

Panacea Biotec Ltd - 531349 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For The Half-Year Ended On 31St March, 2019

 Pursuant to the provisions of Regulation 7(3) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we are enclosing herewith the certificate duly signed by Skyline Financial Services Pvt. Ltd., Share Transfer Agent and Company Secretary of Panacea Biotec Ltd. for the half year ended on 31st March, 2019 in compliance of Regulation 7(2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. This is for your kind information and record please. Kindly acknowledge the receipt.
06-04-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996

 This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we are enclosing herewith the data of shares dematerialized during the month of March, 2019. This is for your information and record please.
06-04-2019
Bigul

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our letter dated April 05, 2019 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the newspaper advertisements regarding Corrigendum-2 for notice of EGM published in the following newspapers on April 06, 2019:- Business Standard, English (all Editions) Desh Sewak, Punjabi Edition This is for your kind information and record please.
06-04-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Corrigendum-2 To The Notice Of Extraordinary General Meeting Of The Company

 In continuation to the Notice dated 26.02.2019 for the Extraordinary General Meeting of the members of Panacea Biotec Limited, held on Monday, 25.03.2019 at 11:30 A.M. at Ambala-Chandigarh Highway, Lalru-140501, Punjab, read with the Corrigendum dated 20.03.2019 published on 21.03.2019 in respect of special resolution to create, offer, issue and allot, in one or more tranches upto 71,11,111 convertible warrants of Rs.180/- each ('Warrant Issue Price'), exercisable into equal number of equity shares of face value of Re.1/- each for cash at a price of Rs.180/- including premium of Rs.179/- per equity share, on a preferential basis to entities/ persons as mentioned in the explanatory statement to the EGM Notice. The said special resolution has been passed by the Members with requisite majority. In this regard Members are hereby informed that the details regarding ultimate beneficial ownership of the proposed Allottees of Warrants in terms of SEBI Circular No. CIR/MIRSD/2/2013 dated 24.01.2013 on 'Guidelines on identification of beneficial ownership', are mentioned in the Corrigendum-2 attached herewith. This is for your kind information and record please.
05-04-2019
Bigul

Panacea Biotec Ltd - 531349 - Closure of Trading Window

 Pursuant to the Company''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company and Material Subsidiaries of the Company from April 03, 2019 till completion of 48 hours from the announcement to the Stock Exchanges of the Audited Financial Results of the Company for the financial year ended March 31, 2019. The date of meeting of the Board of Directors to approve the audited financial results of the Company for the quarter / financial year ended on March 31, 2019 will be informed in due course. This is for your kind information and record please.
03-04-2019
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015

 This is with reference to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, requiring the Company to intimate every amendment to Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. Accordingly, the Board of Directors of the Company has, on March 31, 2019, approved the revision to the same, effective from April 1, 2019 and the same has been made available on the website of the Company. This is for your information and record. Kindly acknowledge the receipt.
01-04-2019
Next Page
Close

Let's Open Free Demat Account